Description
Created On: 2020-07-15
Record Count: 6
Primary Industries
- Delivery
- Medical
- Drugs
- Device
- implants
- Drug Discovery
- Parkinsons Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 294272
The patents include Polymer-based Surgically Implantable Haloperidol Delivery Systems and Methods for Their Production and Use, and, Drug Containing Implants and Methods of Use Thereof.
M2281 Polymer-based Surgically Implantable Haloperidol Delivery Systems and Methods for Their Production and Use 60/242,304
Q3399-PCT Long-Term Delivery Formulations and Methods of Use Thereof US05/00884
S4072 Drug-Containing Implants and Methods od Use Thereof 11/183,232
S4084 Drug containing Implants and Methods of Use Thereof 11/195,845
S4236 Ropinerol Implants for the Treatment of Parkinson’s Disease S No. 60/789,961
LAD to improve the control, consistency and convenience of medication delivery. LAD is comprised of a biodegradable polymer matrix using commonly available medical polymers and an active drug. It is formed into a small implant for injection just below the skin. We designed LAD to improve the control, consistency and convenience of medication delivery.
IPSCIO Record ID: 298788
Ropinirole is used to treat symptoms of Parkinson's disease (stiffness, tremors, muscle spasms, and poor muscle control). Ropinirole is also used to treat restless legs syndrome (RLS).
IPSCIO Record ID: 294293
The joint research is for Implants for the treatment of dopamine associated states, meaning Biodegradable implant containing a dopamine modluating compound.
Licensor patents include Methods for manufacturing delivery systems and systems, and, Modulating burst and release profiles from coestruded implants by treating implant ends, and, Influencing drug release profiles from implants by selectively adjusting the location and amount of drug loading, and, Implant devices that differ by release profile and methods of making and using same.
IPSCIO Record ID: 294273
Licensor will grant an exclusive license to Licensors interest in Research Inventions and Licensors Technology, including, without limitation, all know how and present and future patents, patent applications, certificates of invention, or applications for certificates of invention and any supplemental protection certificates together with any extensions, registrations, confirmations, reissues, substitutions, divisions, continuations or continuations-in-part, reexamination or renewals thereof to the extent necessary for Licensee to make, have made, use, import, sell, have sold and offer for sale the Product in the Field in the Territory.
Licensor grants an exclusive option to license Licensors interest in Research Inventions and Licensor Technology necessary to make, have made, use and sell the Product developed.
With respect to the Project, Licensor shall provide the services of such personnel, laboratory facilities, equipment, chemicals, and other supplies as are required to conduct its activities under this agreement.
Licensors patent is for Methods for Manufacturing delivery Systems and Systems Thereof.
Licensors technology includes:
• Designing and developing depot formulations and devices with biodegradable polymers and non-biodegradable polymers.
• Microparticle compositions to achieve sustained release.
• Nanoparticle compositions to increase bioavailability (includes polymeric and lipid excipients).
• Process technology (laboratory scale, pilot scale, and manufacturing) to fabricate depot formulations, including microparticles.
• Analytical testing useful for the development and registration of depot formulations and devices.
• Design and synthesis of biodegradable polymers.
• Attachment of small molecules and macromolecules to biodegradable polymers]
Licensee designed NP201 to provide continuous delivery of Parkinson’s disease medication in an easy to administer andtolerable dose formulation. After administration, NP201 isdesigned to slowly release ropinirole, an FDA approvedmedication. Based on data from our preclinical studies, webelieve that NP201 has the potential to provide continuoussymptomatic relief for up to two months per dose and tosignificantly decrease the incidence of adverse eventsassociated with current treatments.
IPSCIO Record ID: 282943
Licensee grants to Licensor and Licensor accepts, as from the Effective Date, an exclusive, unlimited, world-wide, perpetual, royalty-free license, with the right to grant sub-licenses to make, use, sell, market and develop any PolyActive Rights B relating to osseouschondral and/or osteochondral plugs, fillers, cement restrictors, or the like, including but not limited to SynPlug(TM) (Licensee License B.)
Licensee grants to Licensor and Licensor accepts, as from the Effective Date, an exclusive, unlimited, world-wide, perpetual, royalty-free license, with the right to grant sub-licenses to make, use, sell, market and develop any PolyActive Rights A and/or PolyActive Rights B related to the use of the PolyActive Technology in a medical device to be used to measure and/or monitor blood glucose (Licensor License AB).
PolyActive shall mean a biodegradable (amphiphilic) poly(ether-ester) multiblock copolymer based on PEGT and PBT.
CHIENNA-Patents shall mean the patents and patent applications defined and listed in Annex I(A) to the ACLA.
PolyActive Rights A shall mean the PolyActive Rights A as defined and listed in Annex 3.2, consisting of the CHIENNA-Patents but not including all previously abandoned and/or transferred patents and patent applications.
6,685,957 – Preparation of fibrous polymer implant containing bioactive agents using wet spinning technique
5,980,948 – Polyetherester copolymers as drug delivery matrices
PolyActive Rights B Shall mean the PolyActive Rights B as defined and listed in Annex 3.1, consisting of the Licensor-Patents but not including (1) all previously abandoned and/or transferred patents and patent applications; (2) the Osteoinduction patent family; and (3) the Cement Restrictor 4th Design.
6,479,418 – Porous ceramic body
6,069,295 – Implant material
Locteron is a controlled release formulation of interferon alfa for the treatment of chronic hepatitis C, currently in Phase IIa studies.
Orthopedic Field shall mean that part of the Licensees patents and patent application which relate to a therapeutic application to the musculoskeletal system, including bone, cartilage, joints, related connective tissues, ligaments, tendons and nerves.
PolyActive technology and its intellectual property in certain strategic areas, including additional applications in orthopedics.
IPSCIO Record ID: 256301
— an exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Technology, the Licensor Program Technology, and the Licensor Confidential Information and
— an exclusive, even as to Licensor, royalty-bearing worldwide sublicense, with a right of further sublicense, under the Licensed University Technology, in each case to make, have made, use, sell or import Licensed Products, Devices and Formulations in the Territory in the Field; and,
— an exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Patent Rights, and the Licensor Program Patent Rights and
— an exclusive, even as to Licensor, worldwide sublicense, with a right of further sublicense, under the Licensed University Patent Rights, in each case to make, have made, use, sell or import Licensed Products, Devices and Formulations in the Territory in the Field; and,
— a non-exclusive sublicense, without a right to further sublicense, to use the Licensor Trademarks with the Licensed Products, Devices and Formulations in the Territory in the Field.
Licensor has extensive expertise in designing and developing innovative ophthalmic drug delivery systems.
Medidur is a tiny injectable, non-erodible, intravitreal device for the treatment of Diabetic Macular Edema (DME), which can lead to blindness. The implant is injected into the back of the eye in an office setting rather than a surgical one. It releases a constant amount of drug and lasts between 18 to 36 months.
The Licensees Compound means any composition of matter, including, small and large molecules, therapeutic proteins, polynucleotides, both double-stranded and singlestranded, and antibodies, or biosimilars.
Collaborative research and license agreement is for Licensor’s controlled drug delivery technologies, including the MedidurTM technology, in ophthalmic applications.
